Aaron Kantoff is Director at Tourmaline Bio, Inc. (TRML). They have made 2 open-market trades across 2 companies since 2021, most recently 2026-03-28.
CIK 0001862734
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
2 open-market purchases totalling $209K since 2021, never a sale. Too few scored purchases to measure a record yet.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.